ATE325894T1 - Verfahren und rechnerprogrammprodukte zur erfassung der biologischen wirkung und/oder aktivität von arzneimitteln, chemischen substanzen und/oder pharmazeuitschen verbindungen auf der basis ihrer effekte auf den methylierungszustand der dna - Google Patents

Verfahren und rechnerprogrammprodukte zur erfassung der biologischen wirkung und/oder aktivität von arzneimitteln, chemischen substanzen und/oder pharmazeuitschen verbindungen auf der basis ihrer effekte auf den methylierungszustand der dna

Info

Publication number
ATE325894T1
ATE325894T1 AT02726125T AT02726125T ATE325894T1 AT E325894 T1 ATE325894 T1 AT E325894T1 AT 02726125 T AT02726125 T AT 02726125T AT 02726125 T AT02726125 T AT 02726125T AT E325894 T1 ATE325894 T1 AT E325894T1
Authority
AT
Austria
Prior art keywords
computer program
program products
biological effect
drugs
activity
Prior art date
Application number
AT02726125T
Other languages
English (en)
Inventor
Alexander Olek
Kurt Berlin
Original Assignee
Epigenomics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epigenomics Ag filed Critical Epigenomics Ag
Application granted granted Critical
Publication of ATE325894T1 publication Critical patent/ATE325894T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT02726125T 2001-03-01 2002-03-01 Verfahren und rechnerprogrammprodukte zur erfassung der biologischen wirkung und/oder aktivität von arzneimitteln, chemischen substanzen und/oder pharmazeuitschen verbindungen auf der basis ihrer effekte auf den methylierungszustand der dna ATE325894T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27248401P 2001-03-01 2001-03-01

Publications (1)

Publication Number Publication Date
ATE325894T1 true ATE325894T1 (de) 2006-06-15

Family

ID=23039991

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02726125T ATE325894T1 (de) 2001-03-01 2002-03-01 Verfahren und rechnerprogrammprodukte zur erfassung der biologischen wirkung und/oder aktivität von arzneimitteln, chemischen substanzen und/oder pharmazeuitschen verbindungen auf der basis ihrer effekte auf den methylierungszustand der dna

Country Status (8)

Country Link
US (2) US7756643B2 (de)
EP (1) EP1379694B1 (de)
JP (1) JP2004532013A (de)
AT (1) ATE325894T1 (de)
CA (1) CA2439779A1 (de)
DE (1) DE60211324T2 (de)
ES (1) ES2264728T3 (de)
WO (1) WO2002070741A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6868344B1 (en) * 2001-06-22 2005-03-15 Vigilant Devices, Llc Controlled substance analysis, wastage disposal and documentation system, apparatus and method
US7871769B2 (en) * 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA2593546A1 (en) * 2004-12-02 2006-07-06 Epigenomics Ag Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
AU2006247708A1 (en) 2005-05-12 2006-11-23 Agc Flat Glass North America, Inc. Low emissivity coating with low solar heat gain coefficient, enhanced chemical and mechanical properties and method of making the same
CA2616601A1 (en) * 2005-07-28 2007-02-08 Oncomethylome Sciences Methylation markers for prognosis and treatment of cancers
WO2007039291A2 (en) * 2005-10-03 2007-04-12 Epigenomics Ag Methods, apparatus and nomograms to determine prostate cancer progression
US20080254470A1 (en) * 2005-10-03 2008-10-16 Epigenomics Ag Methods and Nucleic Acids For the Analysis of Gene Expression Associated With the Prognosis of Cell Proliferative Disorders
US20090264302A1 (en) * 2006-11-01 2009-10-22 Achim Plum Methods, systems and computer program products for determining treatment response biomarkers
GB201007944D0 (en) * 2010-05-12 2010-06-30 Univ Aberystwyth Methods
US20150133383A1 (en) * 2012-05-11 2015-05-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
KR102129066B1 (ko) * 2018-04-11 2020-07-15 한국과학기술연구원 항암 보조치료법의 선택을 위한 혈액 마커 및 이를 이용한 치료법 선택의 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558768A (en) * 1969-12-19 1971-01-26 Sterling Drug Inc Sustained release pharmaceutical compositions
US5739048A (en) * 1994-05-23 1998-04-14 International Business Machines Corporation Method for forming rows of partially separated thin film elements
DE19754482A1 (de) * 1997-11-27 1999-07-01 Epigenomics Gmbh Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke
US6271102B1 (en) * 1998-02-27 2001-08-07 International Business Machines Corporation Method and system for dicing wafers, and semiconductor structures incorporating the products thereof
US6331393B1 (en) * 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis

Also Published As

Publication number Publication date
EP1379694B1 (de) 2006-05-10
WO2002070741A2 (en) 2002-09-12
DE60211324T2 (de) 2007-02-08
WO2002070741A3 (en) 2003-10-30
US20100233722A1 (en) 2010-09-16
CA2439779A1 (en) 2002-09-12
ES2264728T3 (es) 2007-01-16
EP1379694A2 (de) 2004-01-14
US20040029117A1 (en) 2004-02-12
JP2004532013A (ja) 2004-10-21
DE60211324D1 (de) 2006-06-14
US7756643B2 (en) 2010-07-13

Similar Documents

Publication Publication Date Title
DE60211324D1 (de) Verfahren und rechnerprogrammprodukte zur erfassung der biologischen wirkung und/oder aktivität von arzneimitteln, chemischen substanzen und/oder pharmazeuitschen verbindungen auf der basis ihrer effekte auf den methylierungszustand der dna
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
ATE380185T1 (de) Tricyclische verbindungen zur behandlung von entzündlichen- und allergischen erkrankungen: verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE602004030353D1 (de) Formulierungen enthaltend salicylate und deren verwendung zur behandlung von entzündlicher darmerkrankung
DE602004022036D1 (de) Verfahren zur behandlung von atherosklerose, dyslipidämie und verwandten erkrankungen und pharmazeutische zusammensetzungen
DE60128916D1 (de) Neues, physiologisch aktives peptid und dessen verwendung
BR0317358A (pt) Composto de pirrolopiridazina, processo para sua preparação, composição farmacêutica contendo o mesmo, método de prevenção ou tratamento de doenças contendo o mesmo e seu uso
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
DE60223340D1 (de) Serpin-arzneistoffe zur behandlung einer hiv-infektion und verfahren zu deren verwendung
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
DE602005009974D1 (de) Eichung von biologischen oder pharmazeutischen substanzen
DE112004000961D2 (de) Verwendung von Wirksubstanzen zur Vorbeugung oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
ATE530659T1 (de) Modulare transfektionssysteme auf der basis von nukleoproteinfilamenten
ATE356994T1 (de) Screeningverfahren mit pim1-kinase oder pim3- kinase
DE60218843D1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
EP1627927A3 (de) Verfahren, Systeme und Rechnerprogrammprodukte zur Erfassung der biologischen Wirkung und/oder Aktivität von Arzneimitteln, chemischen Substanzen und/oder pharmazeuitschen Verbindungen auf der Basis ihrer Effekte auf den Methylierungszustand der DNA
UY29544A1 (es) Tratamiento de enfermedades usando un sistema mejorado de expresión regulada
DE602004029993D1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
DE602004017214D1 (de) Antibakterielle und/oder gegen protozoen wirksame nitroimidazolderivatverbindungen mit ureasehemmender wirkung, verfahren zur herstellung dieser verbindungen und deren verwendung in pharmazeutischen zusammensetzungen und medikamenten
BRPI0413132A (pt) composições e compostos bicìclicos como inibidores de pdf
DE602004019481D1 (de) Antiandrogen-Oligonukleotide zur Behandlung von Androgen-verwandten Hautkrankheiten, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen und deren Verwendung
EP1184391A3 (de) Acetylcholinrezeptor-Untereinheiten
FR2852841B1 (fr) Composition cosmetique ou pharmaceutique comprenant des acides amines, utilisations et procedes de traitement
ATE407925T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
DK1716128T3 (da) Substituerede 4,5,6,7-tetrahydrobenzothiazol-2-ylaminforbindelser

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties